Delving into the Latest Updates on Inactivated adjuvanted influenza vaccine(LiteVax) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine

Synonyms

TETRALITE

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication-

Originator Organization

Litevax B V

Active Organization

Litevax B V

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The effect of LiteVax Adjuvant supplemented to licensed seasonal influenza vaccine on safety and immunogenicity will be investigated in both younger and older healthy participants. Local and systemic adverse events, and humoral and cellular immune responses will be determined at different time intervals after a single administration. Mode of action of LiteVax Adjuvant will examined by detailed genetic analysis and omics approaches such as transcriptomics, proteomics and metabolomics.

Start Date29 Jan 2024

Sponsor / Collaborator

Litevax B V

NCT05581407

/ CompletedPhase 1

A Randomized First-in-human, Observer-blind, 3-arm Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single Administration of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccine

There is an obvious need for an affordable and more effective seasonal influenza vaccine. TETRALITE is a novel, inactivated, adjuvanted influenza vaccine combining a low dose of a licensed vaccine with the novel, potent LiteVax Adjuvant.
A licensed vaccine (Cohort 1) with a normal dose [15 ug per strain] and no adjuvant will be compared with two TETRALITE study vaccines with 1/5th of the licensed vaccine added with a low (Cohort 2) or high (Cohort 3) dose of LiteVax Adjuvant.

Start Date03 Oct 2022

Sponsor / Collaborator

Litevax B V

[+1]

NCT00522236

/ CompletedPhase 2

A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Elderly Subjects

To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over

Start Date01 Jun 2007

Sponsor / Collaborator-

100 Clinical Results associated with Inactivated adjuvanted influenza vaccine(LiteVax)

Login to view more data

100 Translational Medicine associated with Inactivated adjuvanted influenza vaccine(LiteVax)

Login to view more data

100 Patents (Medical) associated with Inactivated adjuvanted influenza vaccine(LiteVax)

Login to view more data

100 Deals associated with Inactivated adjuvanted influenza vaccine(LiteVax)

Login to view more data